Dudediligence.

Elicio Therapeutics, Inc

ELTXNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Net income, by quarter
−$18.8MSep ’24−$14.0MDec ’24−$11.2MMar ’25−$10.6MJun ’25−$10.1MSep ’25−$7.7MDec ’25−$11.8MMar ’26−$8.2MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$27.5M$2.3Mnone on filenone on filenone on file
Gross profit$27.1M$2.3Mnone on filenone on filenone on file
Operating income−$39.3M−$23.7M−$35.7M−$45.0M−$37.7M
Net income−$54.6M−$28.2M−$35.2M−$51.9M−$39.6M
Operating cash flow−$52.6M−$22.2M−$32.7M−$37.1M−$37.0M
Free cash flow−$53.0M−$22.8M−$32.8M−$37.2M−$37.0M
Cash$88.8M$6.2M$12.9M$17.6M$18.6M
Debt$0.00none on filenone on file$20.0M$9.4M
Shares outstanding30.0M320.3K9.6M11.0M17.8M